Literature DB >> 19001061

Lithium-associated hyperparathyroidism: report of four cases and review of the literature.

Auryan Szalat1, Haggi Mazeh, Herbert R Freund.   

Abstract

CONTEXT: Lithium-associated hyperparathyroidism (LAH) was first described in 1973 but many issues remain in question regarding the pathophysiology as well as the appropriate management of this condition.
OBJECTIVE: Report of four new cases and review of the literature.
RESULTS: We describe two males and two females, treated for more than 10 years with lithium due to bipolar disorder, who developed LAH. All underwent parathyroidectomy. In three cases (75%), pathology revealed multiglandular disease, with hyperplasia or two parathyroid adenomas. We observed a cure status in three (75%) of the operated patients. The fourth patient had a residual disease, but had controlled hypercalcemia under the calcimimetic drug cinacalcet. We also observed the association of LAH with incidental papillary thyroid carcinoma in two patients. Review of the literature identified a higher prevalence of LAH in women than men (four out of one) and a controversy in regard to the prevalence of multiglandular disease. As a result, there is no consensus regarding the preferred surgical procedure. The use of cinacalcet as an effective treatment of LAH was previously described in only five cases.
CONCLUSION: In our view, there are apparently two different mechanisms leading to LAH: exacerbation of a pre-existing state of hyperparathyroidism and multiglandular disease. For uncontrolled hypercalcemia, parathyroidectomy is recommended. The issue of routine four-gland exploration and subtotal parathyroidectomy versus intraoperative PTH-determination-guided excision of enlarged glands is still unresolved. The use of the recently developed calcimimetics may offer an alternative to patients who are not candidates for surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001061     DOI: 10.1530/EJE-08-0620

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  22 in total

1.  Multiple spontaneous tendon ruptures from enthesis failure in primary hyperparathyroidism: a case report and review of imaging findings.

Authors:  Maaz Mohammad Salah; Yan Rong Yong; Wee Teng Poh; Le Roy Chong
Journal:  Skeletal Radiol       Date:  2018-10-23       Impact factor: 2.199

Review 2.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

3.  Potentiation of Endocrine Adverse Effects of Lithium by Enalapril and Verapamil.

Authors:  R Krysiak; B Okopien
Journal:  West Indian Med J       Date:  2014-08-29       Impact factor: 0.171

4.  Lithium for older adults with bipolar disorder: Should it still be considered a first-line agent?

Authors:  Kenneth I Shulman
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

5.  Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy.

Authors:  Anita R Skandarajah; F Fausto Palazzo; Jean-François Henry
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

6.  Every reason to discontinue lithium.

Authors:  Manuel E Fuentes Salgado; Bruce Sutor; Robert C Albright; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2014-11-08

Review 7.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

8.  Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation.

Authors:  Auryan Szalat; Michal Shahar; Shoshana Shpitzen; Boaz Nachmias; Gabriel Munter; David Gillis; Ronen Durst; Dror Mevorach; Eran Leitersdorf; Vardiella Meiner; Haim Rosen
Journal:  Endocrine       Date:  2014-08-05       Impact factor: 3.633

Review 9.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus.

Authors:  Nihat Aksakal; Candaş Erçetin; Beyza Özçınar; Ferihan Aral; Yeşim Erbil
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.